New LRA-Supported Study Provides Clue to Potential New Treatment Target
February 27, 2020 A new study supported by the Lupus Research Alliance discovered that molecules called type II interferons can trigger the immune system to over-produce the B cells that cause lupus inflammation. Type I interferons have already been shown to be very important in lupus which has led to exciting new drugs like anifrolumab […]
Nephritis
Lupus nephritis is kidney inflammation caused by systemic lupus erythematosus (SLE or lupus). SLE is an autoimmune disease—a disorder in which the body’s immune system attacks the body’s own cells and organs. Up to 60 percent of people with SLE are diagnosed with lupus nephritis, which can lead to significant illness and even death. Source: […]
LRA-Funded Study Finds Lazy Enzyme that Triggers Autoimmunity
April 14, 2021 Dr. Boris Reizis and his team, working with a group of clinical rheumatologists led by Dr. Jill Buyon, have made a connection between an enzyme that prevents people’s immune systems from reacting to their own DNA and lupus activity. In a paper just published in the Journal of Experimental Medicine they report […]
Promising News from Major Medical Meeting, EULAR
Updated June 5, 2020 One of the largest meetings for rheumatologists went virtual this year to enable scientists from around the world to share their latest findings amid the COVID-19 pandemic. EULAR, the e-Congress of the European League Against Rheumatism, runs June 3 -6, and LRA is pleased to share promising results from clinical trials […]
Grant Updates
The Lupus Research Alliance supports the full range of research from fundamental through translational and clinical studies. Most recently, the organization awarded six Novel Research Grants and seven Target Identification in Lupus (TIL) grants. PROMISING NOVEL GRANT AWARDS: The Lupus Research Alliance supports game-changing lupus research, and our Novel Research Grant program is exploring lupus […]
Q&A with Selena Gomez
Q: Why are you supporting the LRA’s Lift Up Lupus campaign? A: This was a tough year for all of us, and I am inspired by the sense of optimism conveyed by the LRA’s Lift Up Lupus campaign – and incredibly inspirational stories. There are many misconceptions surrounding lupus, and I hope the Lift Up […]
LRA Addressing Health Disparities Among Vulnerable Groups
February 20, 2020 The Lupus Research Alliance (LRA) works hard, often in concert with organizations like the National Minority Quality Forum to alleviate disparities in healthcare among groups at particular risk for lupus, including African-Americans as the group hardest hit by the disease. Several programs educate healthcare providers, patients and the public to better recognize […]
Meet Unstoppable Advocate for Minority Health Christopher Reed
Determined to alleviate healthcare disparities for minorities, J. Christopher Reed, JD, urges our lupus community to use the power of National Minority Health Month to spotlight the issue this April. First diagnosed at 16, Christopher fought debilitating lupus symptoms to graduate college in eight years and then Tulane University Law School in three. Throughout college […]
Catalyzing Research
First Lupus Nephritis Drug Approved In December of 2020, lupus research attained another major milestone-one which stemmed from a critical investigation funded by our organization. Now, with the FDA’s approval, belimumab (Benlysta®) can be used as a therapeutic for lupus nephritis. “An effective treatment developed specifically for lupus nephritis has been desperately needed,” commented Lupus […]
Two New Drugs Receive FDA Approval
May 1, 2021 “This is a historic moment in lupus with two new drug approvals for lupus nephritis just over a month,” enthused Kenneth M. Farber, LRA President and CEO. The LRA is excited to share that the U.S. Food and Drug Administration (FDA) has approved the use of voclosporin (Lupkynis™) as the first oral […]
Downloads
Accelerating Medicines Partnership Completes Key Phase
September 24, 2019 The Accelerating Medicines Partnership (AMP) RA/Lupus Program, a joint effort involving the National Institutes of Health (NIH), the Foundation for NIH, pharmaceutical companies, and non-profit organizations such as the Lupus Research Alliance, has reached a milestone, finishing an important phase of its studies. Researchers with the AMP RA/Lupus Program have published a […]